ID: h-aadf6dc168
Hypothesis

APOE4 alters the accessible-cholesterol threshold sensed by SCAP through ER membrane composition changes

A more conjectural model is that APOE4-driven lipid remodeling changes ER membrane organization so that SCAP perceives cholesterol insufficiency at a given sterol mass.
🧬 SCAP🩺 molecular-biology🎯 Composite 42%💱 $0.48▲15.3%proposed
molecular biology
EvidencePending (0%)📖 0 cit🗣 1 debates 7 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.49 (15%) Evidence 0.31 (15%) Novelty 0.74 (12%) Feasibility 0.43 (12%) Impact 0.34 (12%) Druggability 0.29 (10%) Safety 0.26 (8%) Competition 0.71 (6%) Data Avail. 0.30 (5%) Reproducible 0.29 (5%) KG Connect 0.50 (8%) 0.420 composite

🧪 Overview

A more conjectural model is that APOE4-driven lipid remodeling changes ER membrane organization so that SCAP perceives cholesterol insufficiency at a given sterol mass. This is conceptually interesting and compatible with accessible-cholesterol biology, but currently lacks direct APOE4-specific evidence and remains below funding priority.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["APOE4 Isoform<br/>Arg112-Cys158 Structure"]
    B["LRP1 Receptor Binding<br/>Hepatic and Neuronal Uptake"]
    C["TREM2 Engagement<br/>Microglial State Transition"]
    D["DAM Identity<br/>Disease-Associated Microglia"]
    E["Lipid Metabolism<br/>Cholesterol Efflux Defect"]
    F["Amyloid Clearance<br/>Reduced A-beta Uptake"]
    G["Tau Hyperphosphorylation<br/>GSK3B/CDK5 Activation"]
    H["Neurofibrillary Tangles<br/>Intraneuronal Pathology"]
    I["Synaptic Dysfunction<br/>Neuronal Network Disruption"]
    J["Cognitive Decline<br/>Progressive Dementia"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    A --> G
    F -.->|"accelerates"| G
    G --> H
    D --> I
    H --> J
    I --> J
    style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style J fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix7 supports3 contradicts
Supports
SCAP responds to the accessible cholesterol fraction in ER membranes rather than simply total cholesterol mass.
Supports
APOE4 causes broad intracellular lipid-trafficking abnormalities that could plausibly alter membrane composition.
Supports
The ER cholesterol sensor SCAP promotes CARTS biogenesis at ER-Golgi membrane contact sites.
J Cell Biol2021PMID:33156328
Supports
Dysfunction of cholesterol sensor SCAP promotes inflammation activation in THP-1 macrophages.
Exp Cell Res2018PMID:29596892
Supports
Control of innate immunity and lipid biosynthesis in neurodegeneration.
Front Mol Neurosci2024PMID:39156128
Supports
SCAP, an ER sensor that regulates cell cholesterol.
Dev Cell2002PMID:12361593
Supports
Assaying Sterol-Regulated ER-to-Golgi Transport of SREBP Cleavage-Activating Protein Using Immunofluorescence Microscopy.
Methods Mol Biol2023PMID:36512249
Contradicts
No direct evidence links APOE4 to a shifted SCAP cholesterol threshold in ER membranes.
Contradicts
Apparent changes in accessible cholesterol could instead reflect altered sterol mass, probe artifacts, or generalized membrane stress.
Contradicts
Interventions such as SOAT1/ACAT1 modulation are broad and may perturb lipid droplets, ER stress responses, and myelination.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SCAP

No curated PDB or AlphaFold mapping for SCAP yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SCAP from GTEx v10.

Cerebellum70.3 Cerebellar Hemisphere63.1 Cortex35.9 Frontal Cortex BA930.7 Nucleus accumbens basal ganglia27.9 Spinal cord cervical c-125.4 Hypothalamus24.4 Caudate basal ganglia24.2 Anterior cingulate cortex BA2424.1 Putamen basal ganglia22.1 Hippocampus20.5 Amygdala20.3 Substantia nigra18.7median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SCAP →

No DepMap CRISPR Chronos data found for SCAP.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.7%
Volatility
Low
0.0154
Events (7d)
2
Price History
▲15.3%

💾 Resource Usage

LLM Tokens
17,104
$0.0513
Total Cost
$0.0513

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF human iPSC-derived neurons carrying APOE4/4 are treated with a range of extracellular cholesterol concentrations (0-20 µg/mL for 6 hours), THEN nuclear SREBP2 accumulation will occur at significantAPOE4/4 neurons will show half-maximal SREBP2 nuclear translocation at ≤5 µg/mL cholesterol versus ≥8 µg/mL for APOE3/3 neurons, reflecting a lowered threshold — no observation —pending0.45
IF APOE4/4 astrocytes are compared to APOE3/3 astrocytes under sterol-replete conditions (serum-free media with 10 µg/mL cholesterol), THEN total ER membrane accessible cholesterol, measured by cholesReduced accessible ER cholesterol in APOE4/4 astrocytes will trap more SCAP bound to Insig in the ER, preventing SCAP-SREBP trafficking to the Golgi, with Insig— no observation —pending0.40
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF human iPSC-derived neurons carrying APOE4/4 are treated with a range of extracellular cholesterol concentrations (0-20 µg/mL for 6 hours), THEN nuclear SREBP2 accumulation will occur at significantly lower cholesterol concentrations compared to APOE3/3 neurons, with a leftward shift of ≥40% in th
Predicted outcome: APOE4/4 neurons will show half-maximal SREBP2 nuclear translocation at ≤5 µg/mL cholesterol versus ≥8 µg/mL for APOE3/3 neurons, reflecting a lowered
Falsification: APOE4/4 and APOE3/3 neurons exhibit identical cholesterol dose-response curves for nuclear SREBP2 accumulation, with overlapping EC50 values and 95% CI, indicating APOE4 does not alter the SCAP choles
pendingconf 40%
IF APOE4/4 astrocytes are compared to APOE3/3 astrocytes under sterol-replete conditions (serum-free media with 10 µg/mL cholesterol), THEN total ER membrane accessible cholesterol, measured by cholesterol oxidase accessibility assay, will be ≥30% lower in APOE4/4 cells, and this reduction will corr
Predicted outcome: Reduced accessible ER cholesterol in APOE4/4 astrocytes will trap more SCAP bound to Insig in the ER, preventing SCAP-SREBP trafficking to the Golgi,
Falsification: ER membrane accessible cholesterol levels are statistically indistinguishable between APOE4/4 and APOE3/3 astrocytes (difference <15%, p>0.05), or SCAP-Insig binding does not correlate with accessible
Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.